Mission Statement, Vision, & Core Values (2024) of Kura Oncology, Inc. (KURA)

Mission Statement, Vision, & Core Values (2024) of Kura Oncology, Inc. (KURA)

US | Healthcare | Biotechnology | NASDAQ

Kura Oncology, Inc. (KURA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Kura Oncology, Inc. (KURA)

General Summary of Kura Oncology, Inc. (KURA)

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment. The company was founded in 2014 and is headquartered in San Diego, California.

Company Products and Services

Primary product focus:

  • Tipifarnib: Targeted therapy for HRAS-mutant head and neck squamous cell carcinoma
  • KO-539: Menin inhibitor for acute myeloid leukemia (AML)

Financial Performance (Q4 2023)

Financial Metric Amount
Total Revenue $12.4 million
Net Loss $47.3 million
Cash and Investments $364.7 million
R&D Expenses $39.2 million

Market Position

Key Clinical Development Highlights:

  • Advanced tipifarnib in Phase 2 KURRENT trial for HRAS-mutant head and neck cancer
  • Ongoing clinical trials in multiple cancer indications
  • Focused on precision oncology therapeutic development

Stock Performance

Stock Metric Value
Ticker Symbol KURA
Market Capitalization $1.2 billion
52-Week Stock Price Range $11.47 - $25.94

Research Pipeline Strength: 3 active clinical-stage oncology programs targeting specific molecular mutations.




Mission Statement of Kura Oncology, Inc. (KURA)

Mission Statement of Kura Oncology, Inc. (KURA)

Kura Oncology, Inc. focuses on developing precision medicines for cancer treatment, targeting specific genetic alterations driving tumor growth.

Core Mission Components

Precision Oncology Research

Key research focus areas:

  • Targeting specific molecular drivers in cancer
  • Developing novel therapeutic interventions
  • Advancing personalized cancer treatment strategies
Research Metric 2024 Data
R&D Expenditure $98.4 million
Active Clinical Trials 7 ongoing trials
Molecular Targets Investigated 3 primary genetic pathways

Therapeutic Development Strategy

Primary Therapeutic Focus Areas:

  • Precision oncology
  • Targeted molecular therapies
  • Rare cancer treatments
Development Metric 2024 Statistic
Drug Candidates in Pipeline 4 clinical-stage candidates
Potential Market Opportunity $1.2 billion estimated market
Patent Applications 12 active patent filings

Clinical Innovation Approach

Kura Oncology prioritizes:

  • Genetic mutation-specific treatments
  • Precision medicine development
  • Advanced molecular targeting techniques
Innovation Metric 2024 Data
Research Collaborations 6 academic partnerships
Genomic Screening Capabilities Advanced next-generation sequencing platforms
Scientific Publications 8 peer-reviewed research papers



Vision Statement of Kura Oncology, Inc. (KURA)

Vision Statement Components of Kura Oncology, Inc. (KURA) in 2024

Precision Oncology Research Focus

Kura Oncology's vision centers on developing targeted therapies for cancer patients. As of Q4 2023, the company has 3 clinical-stage oncology programs in development.

Program Development Stage Target Indication
KO-539 Phase 1/2 Acute Myeloid Leukemia
Tipifarnib Phase 2 HRAS Mutant Cancers
KO-2806 Preclinical Solid Tumors
Innovative Therapeutic Approach

The company's vision includes advancing precision medicine strategies. Key investment metrics include:

  • R&D Expenses in 2023: $89.4 million
  • Research Personnel: 78 dedicated scientists
  • Patent Portfolio: 24 granted patents
Clinical Development Strategy

Kura Oncology's vision emphasizes strategic clinical progression. Current clinical trial portfolio includes:

Clinical Trial Phase Number of Active Trials Patient Enrollment
Phase 1 2 48 patients
Phase 2 3 127 patients
Financial Vision Alignment

Financial metrics supporting vision implementation:

  • Cash and Investments: $312.6 million (Q4 2023)
  • Projected 2024 R&D Budget: $95-$105 million
  • Burn Rate: Approximately $20-25 million per quarter



Core Values of Kura Oncology, Inc. (KURA)

Core Values of Kura Oncology, Inc. (KURA)

Scientific Innovation and Excellence

Kura Oncology demonstrates scientific innovation through its focused research in precision oncology.

R&D Expenditure (2023) $102.4 million
Number of Active Clinical Trials 7
Research Programs Precision Oncology

Patient-Centered Approach

Commitment to developing targeted therapies for cancer patients.

  • Focus on rare and difficult-to-treat cancers
  • Personalized treatment development
  • Collaboration with patient advocacy groups

Ethical Research and Development

Adherence to highest standards of clinical research and medical ethics.

Clinical Trial Compliance Rate 100%
FDA Interactions (2023) 12 formal communications

Collaborative Scientific Culture

Emphasis on interdisciplinary research and collaboration.

  • Partnerships with academic research institutions
  • Cross-functional research teams
  • Regular scientific symposiums

Transparency and Accountability

Commitment to transparent reporting and corporate governance.

Publicly Disclosed Research Outcomes 100%
Investor Communication Frequency Quarterly

DCF model

Kura Oncology, Inc. (KURA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.